Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Analyst consensus is “Moderate Buy”: Eight of ten analysts rate Pyxis Oncology a buy, while one rates it a hold and one a sell. The average 12-month price target is $7.50, compared with the stock’s opening price of $3.89.
• Recent financial results fell short of expectations: Pyxis reported a quarterly loss of $0.40 per share, missing the consensus estimate of a $0.35 loss. Analysts expect a full-year loss of approximately $1.21 per share.
• Institutional ownership remains significant: Hedge funds and other institutional investors own 39.07% of PYXS, with several firms recently increasing stakes or initiating new positions.

Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) has been given an average rating of "Moderate Buy" by the ten analysts that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and eight have given a buy recommendation to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $7.50.

Several research firms have commented on PYXS. HC Wainwright reaffirmed a "buy" rating and set a $7.00 price objective on shares of Pyxis Oncology in a report on Tuesday, August 18th. Wells Fargo & Company began coverage on shares of Pyxis Oncology in a research note on Monday, August 3rd. They set an "overweight" rating and a $12.00 price target on the stock. Wall Street Zen lowered shares of Pyxis Oncology from a "hold" rating to a "sell" rating in a research note on Saturday, May 16th. Leerink Partners dropped their target price on Pyxis Oncology from $9.00 to $7.00 and set an "outperform" rating on the stock in a research report on Thursday, July 2nd. Finally, Weiss Ratings lowered Pyxis Oncology from a "sell (d-)" rating to a "sell (e+)" rating in a report on Tuesday, June 30th.

Pyxis Oncology Price Performance

Shares of PYXS stock opened at $3.89 on Wednesday. The firm has a market cap of $324.46 million, a P/E ratio of -2.76 and a beta of 1.34. The company has a 50 day moving average of $3.00 and a 200-day moving average of $2.20. Pyxis Oncology has a 12-month low of $1.03 and a 12-month high of $5.55.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.05). As a group, equities analysts expect that Pyxis Oncology will post -1.21 EPS for the current year.

Institutional Investors Weigh In On Pyxis Oncology

A number of institutional investors and hedge funds have recently modified their holdings of PYXS. Bank of America Corp DE grew its stake in Pyxis Oncology by 20.3% during the fourth quarter. Bank of America Corp DE now owns 53,745 shares of the company's stock valued at $84,000 after acquiring an additional 9,062 shares in the last quarter. Acadian Asset Management LLC purchased a new position in shares of Pyxis Oncology during the 1st quarter valued at $81,000. XTX Topco Ltd bought a new position in shares of Pyxis Oncology in the second quarter worth $40,000. Marshall Wace LLP purchased a new stake in shares of Pyxis Oncology in the second quarter worth $163,000. Finally, Qube Research & Technologies Ltd boosted its stake in Pyxis Oncology by 128.4% during the second quarter. Qube Research & Technologies Ltd now owns 103,063 shares of the company's stock valued at $113,000 after buying an additional 57,935 shares during the period. 39.07% of the stock is owned by hedge funds and other institutional investors.

About Pyxis Oncology

Pyxis Oncology NASDAQ: PYXS is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company's platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.